Recent developments in rare diseases highlighted the interest to perform drug screening to repurpose new drugs as revealed with the discovery of small molecules modulators of SMN expression for spinal muscular atrophy (SMA) (Jarecki et al., 2005), cardiac glycosides as modulators of myotonic dystrophy 1 (DM1) (Maury et al., 2019) or metformin as a modulator of progerin expression for Hutchinson–Gilford progeria syndrome (HGPS) (Egesipe et al., 2016). Here, LMNA is linked to myotonic dystrophy type 1.